• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology

    1/26/22 9:31:00 AM ET
    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AXLA alert in real time by email

    CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.

    (PRNewsfoto/Senda Biosciences)

    Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology

    "Stuart is one of the industry's foremost experts in translating RNA science into meaningful new therapies and his experience is perfectly suited for Senda at this moment, as we leverage the power of evolution to discover and develop programmable medicines," said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering. "We've recently generated significant momentum programming medicines that use the codes provided by nature to target cells and tissues of interest, with the potential to surpass current industry standards. We're thrilled to work with Stuart to continue that momentum, and on behalf of our team and board, we welcome Stuart to Senda and look forward to his contributions."

    "Senda made tremendous progress recently advancing its platform, generating exciting data in large animal studies and disease-relevant models that demonstrate the ability to effectively co-opt natural mechanisms to program human cells in vivo. This accomplishment offers great potential for the development of programmable therapies that can be directed to specific tissues, using nucleic acids as well as other modalities," said Dr. Milstein. "The most transformative thing about this approach is that once you have demonstrated it works, the potential for new therapies is exponential. I'm truly excited to be joining Senda and look forward to an exciting journey."

    Before joining Senda, Stuart served as Vice President of Platform Biology at Korro Bio, where he built and led the high-throughput screening and platform biology functions and served on the leadership team. At Korro, he helped establish their ADAR-mediated RNA editing platform, enabling the company to transition from seed funding through Series B. Previously, at Alnylam, Stuart helped establish and then led the RNAi Lead Development group responsible for the lead development and optimization of all candidates in the Alnylam pipeline. He contributed to the discovery and optimization of multiple products, including Onpattro™, the first-ever approved RNAi therapeutic, Givlarri™, the first approved siRNA GalNac conjugate, and other approved products for orphan and large indications. He also initiated work on the delivery of siRNAs to the central nervous system (CNS), co-led the CNS delivery platform, and made substantial contributions across Alnylam's platform, including optimizing siRNA design for GalNAc conjugates.

    Dr. Milstein has trained as a research fellow in the Department of Genetics at Harvard Medical School and Dana-Farber Cancer Institute, where he focused on genomics and proteomics. He received his Ph.D. through the genetics program at Cold Spring Harbor Laboratory and Stony Brook University, studying the genetics of apoptosis.

    About Senda Biosciences

    Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both from within (mRNA) and from outside – from what surrounds them. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda's proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering. For more information, visit sendabiosciences.com or follow us on Twitter and LinkedIn.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $140 billion in aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (NASDAQ:AXLA), Codiak BioSciences (NASDAQ:CDAK) Denali Therapeutics (NASDAQ:DNLI), Evelo Biosciences (NASDAQ:EVLO), Foghorn Therapeutics (NASDAQ:FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

    Contact

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/senda-biosciences-appoints-stuart-milstein-phd-as-svp-and-head-of-platform-biology-301468711.html

    SOURCE Senda Biosciences

    Get the next $AXLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXLA
    $CDAK
    $DNLI
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Denali Therapeutics Inc.
    $DNLI
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Denali Therapeutics Inc.
    $DNLI
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gallagher Neil

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:04:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Duty Stuart

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:03:21 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Gallagher Neil

      3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:01:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

      For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

      9/7/21 4:11:11 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    SEC Filings

    See more
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Sana Biotechnology Inc.

      S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:32:51 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Sana Biotechnology Inc.

      10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:10:02 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

      Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B-cell depletion using a surrogate for SG299, an in vivo CAR T with CD8-targeted fusogen delivery of a CD19-direc

      5/8/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

      4/23/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce

      3/13/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care